Quinoxalinyl carboxylic acid derivatives

Details Quinoxalinyl carboxylic acid derivatives Quinoxalinyl carboxylic acid derivatives

2003-02-06

2004-02-10

Rao, Deepak (Department: 1624)

Organic compounds -- part of the class 532-570 series

Organic compounds

Nitrogen attached directly or indirectly to the purine ring...

C514S249000

Reexamination Certificate

active

06689886

ABSTRACT:

BACKGROUND OF THE INVENTION
The present invention relates to novel hexanoic acid derivatives, methods of use and pharmaceutical compositions containing them.
The compounds of the invention are useful in the preparation and use of compounds of formula 1, which are potent and selective inhibitors of MIP-1&agr; binding to its receptor CCR1 found on inflammatory and immunomodulatory cells (preferably leukocytes and lymphocytes). The CCR1 receptor is also sometimes referred to as the CC-CKR1 receptor. The compounds of formula I also inhibit MIP-1&agr; (and the related chemokines shown to interact with CCR1 (e.g., RANTES and MCP-3)) induced chemotaxis of THP-1 cells and human leukocytes and are potentially useful for the treatment or prevention of autoimmune diseases (such as rheumatoid arthritis, type I diabetes (recent onset), inflammatory bowel disease, optic neuritis, psoriasis, multiple sclerosis, polymyalgia rheumatica, uveitis, and vasculitis), acute and chronic inflammatory conditions (such as osteoarthritis, adult Respiratory Distress Syndrome, Respiratory Distress Syndrome of infancy, ischemia reperfusion injury, and glomerulonephritis), allergic conditions (such as asthma and atopic dermatitis), infection associated with inflammation (such as viral inflammation (including influenza and hepatitis) and Guillian-Barre), chronic bronchitis, xeno-transplantation, transplantation tissue rejection (chronic and acute), organ rejection (chronic and acute), atherosclerosis, restenosis, HIV infectivity (co-receptor usage), and granulomatous diseases (including sarcoidosis, leprosy and tuberculosis).
MIP-1&agr; and RANTES are soluble chemotactic peptides (chemokines) which are produced by inflammatory cells, in particular CD8+ lymphocytes, polymorphonuclear leukocytes (PMNs) and macrophages,
J.Biol. Chem
., 270 (30) 29671-29675 (1995). These chemokines act by inducing the migration and activation of key inflammatory and immunomodulatory cells. Elevated levels of chemokines have been found in the synovial fluid of rheumatoid arthritis patients, chronic and rejecting tissue transplant patients and in the nasal secretions of allergic rhinitis patients following allergen exposure (Teran, et al.,
J. Immunol
., 1806-1812 (1996), and Kuna et al.,
J. Allergy Clin. Immunol
. 321 (1994)). Antibodies which interfere with the chemokine/receptor interaction by neutralizing MIP1&agr; or gene disruption have provided direct evidence for the role of MIP-1 and RANTES in disease by limiting the recruitment of monocytes and CD8+lymphocytes (Smith et al.,
J. Immunol
, 153, 4704 (1994) and Cook et al.,
Science
, 269, 1583 (1995)). Together this data demonstrates that CCR1 antagonists would be an effective at treatment of several immune based diseases.
SUMMARY OF THE INVENTION
The present invention relates to compounds of the formula XXXI
or the pharmaceutically acceptable salt thereof; wherein
R
1
is quinoxalinyl optionally substituted with one or more substituents independently selected from the group consisting of hydrogen, deuterium, halo, CN, (C
1
-C
6
)alkyl optionally substituted with one or more fluorine atoms, hydroxy, hydroxy-(C
1
-C
6
)alkyl, (C
1
-C
6
)alkoxy optionally substituted with one or more fluorine atoms, (C
1
-C
6
)alkoxy(C
1
-C
6
)alkyl, HO—(C═O)—, (C
1
-C
6
)alkyl-O—(C═O)—, HO—(C═O)—(C
1
-C
6
)alkyl, (C
1
-C
6
)alkyl-O—(C═O)—(C
1
-C
6
)alkyl, (C
1
-C
6
)alkyl-(C═O)—O—, (C
1
-C
6
)alkyl-(C═O)—O—(C
1
-C
6
)alkyl, H(O═C)—, H(O═C)—(C
1
-C
6
)alkyl, (C
1
-C
6
)alkyl(O═C)—, (C
1
-C
6
)alkyl(O═C)—(C
1
-C
6
)alkyl, NO
2
, amino, (C
1
-C
6
)alkylamino, [(C
1
-C
6
)alkyl]
2
amino, amino(C
1
-C
6
)alkyl, (C
1
-C
6
)alkylamino(C
1
-C
6
)alkyl, [(C
1
-C
6
)alkyl]
2
amino(C
1
-C
6
)alkyl, H
2
N—(C═O)—, (C
1
-C
6
)alkyl-NH—(C═O)—, [(C
1
-C
6
)alkyl]
2
N—(C═O)—, H
2
N(C═O)—(C
1
-C
6
)alkyl, (C
1
-C
6
)alkyl-HN(C═O)—(C
1
-C
6
)alkyl, [(C
1
-C
6
)alkyl]
2
N—(C═O)—(C
1
-C
6
)alkyl, H(O═C)—NH—, (C
1
-C
6
)alkyl(C═O)—NH, (C
1
-C
6
)alkyl(C═O)—[NH](C
1
-C
6
)alkyl, (C
1
-C
6
)alkyl(C═O)—[N(C
1
-C
6
)alkyl](C
1
-C
6
)alkyl, (C
1
-C
6
)alkyl-S—, (C
1
-C
6
)alkyl-(S═O)—, (C
1
-C
6
)alkyl-SO
2
—, (C
1
-C
6
)alkyl-SO
2
—NH—, H
2
N—SO
2
—, H
2
N—SO
2
—(C
1
-C
6
)alkyl, (C
1
-C
6
)alkylHN—SO
2
—(C
1
-C
6
)alkyl, [(C
1
-C
6
)alkyl]
2
N—SO
2
—(C
1
-C
6
)alkyl, CF
3
SO
3
—, (C
1
-C
6
)alkyl-SO
3
—, phenyl, (C
3
-C
10
)cycloalkyl, (C
2
-C
9
)heterocycloalkyl, and (C
2
-C
9
)heteroaryl;
R
2
is phenyl-(CH
2
)
m
—, naphthyl-(CH
2
)
m
—, (C
3
-C
10
)cycloalkyl-(CH
2
)
m
—, (C
1
-C
6
)alkyl or (C
2
-C
9
)heteroaryl-(CH
2
)
m
—, wherein m is an interger from zero to four; wherein each of said phenyl, naphthyl, (C
3
-C
10
)cycloalkyl or (C
2
-C
9
)heteroaryl moieties of said phenyl-(CH
2
)
m
—, naphthyl-(CH
2
)
m
—, (C
3
-C
10
)cycloalkyl-(CH
2
)
m
— or (C
2
-C
9
)heteroaryl-(CH
2
)
m
— groups may optionally be substituted with one or more substituents independently selected from hydrogen, deuterium, halo, CN, (C
1
-C
6
)alkyl optionally substituted with one or more fluorine atoms, hydroxy, hydroxy-(C
1
-C
6
)alkyl, (C
1
-C
6
)alkoxy optionally substituted with one or more fluorine atoms, (C
1
-C
6
)alkoxy(C
1
-C
6
)alkyl, HO—(C═O)—, (C
1
-C
6
)alkyl-O—(C═O)—, HO—(C═O)—(C
1
-C
6
)alkyl, (C
1
-C
6
)alkyl-O—(C═O)—(C
1
-C
6
)alkyl, (C
1
-C
6
)alkyl-(C═O)—O—, (C
1
-C
6
)alkyl-(C═O)—O—(C
1
-C
6
)alkyl, H(O═C)—, H(O═C)—(C
1
-C
6
)alkyl, (C
1
-C
6
)alkyl(O═C)—, (C
1
-C
6
)alkyl(O═C)—(C
1
-C
6
)alkyl, NO
2
, amino, (C
1
-C
6
)alkylamino, [(C
1
-C
6
)alkyl]
2
amino, amino(C
1
-C
6
)alkyl, (C
1
-C
6
)alkylamino(C
1
-C
6
)alkyl, [(C
1
-C
6
)alkyl]
2
amino(C
1
-C
6
)alkyl, H
2
N—(C═O)—, (C
1
-C
6
)alkyl-NH—(C═O)—, [(C
1
-C
6
)alkyl]
2
N—(C═O)—, H
2
N(C═O)—(C
1
-C
6
)alkyl, (C
1
-C
6
)alkyl-HN(C═O)—(C
1
-C
6
)alkyl, [(C
1
-C
6
)alkyl]
2
N—(C═O)—(C
1
-C
6
)alkyl, H(O═C)—NH—, (C
1
-C
6
)alkyl(C═O)—NH, (C
1
-C
6
)alkyl(C═O)—[NH](C
1
-C
6
)alkyl, (C
1
-C
6
)alkyl(C═O)—[N(C
1
-C
6
)alkyl](C
1
-C
6
)alkyl, (C
1
-C
6
)alkyl-S—, (C
1
-C
6
)alkyl-(S═O)—, (C
1
-C
6
)alkyl-SO
2
—, (C
1
-C
6
)alkyl-SO
2
—NH—, H
2
N—SO
2
—, H
2
N—SO
2
—(C
1
-C
6
)alkyl, (C
1
-C
6
)alkylHN—SO
2
—(C
1
-C
6
)alkyl, [(C
1
-C
6
)alkyl]
2
N—SO
2
—(C
1
-C
6
)alkyl, CF
3
SO
3
—, (C
1
-C
6
)alkyl-SO
3
—, phenyl, phenoxy, benzyloxy, (C
3
-C
10
)cycloalkyl, (C
2
-C
9
)heterocycloalkyl, and (C
2
-C
9
)heteroaryl;
R
3
is hydrogen, deuterium, (C
1
-C
10
)alkyl, (C
3
-C
10
)cycloalkyl-(CH
2
)
n
—, (C
2
-C
9
)heterocycloalkyl-(CH
2
)
n
—, (C
2
-C
9
)heteroaryl-(CH
2
)
n
— or aryl-(CH
2
)
n
—; wherein n is an interger from zero to six;
wherein said R
3
(C
1
-C
10
)alkyl group may optionally be-substituted with one or more substituents, independently selected from hydrogen, deuterium, halo, CN, (C
1
-C
6
)alkyl optionally substituted with one or more fluorine atoms, hydroxy, hydroxy-(C
1
-C
6
)alkyl, (C
1
-C
6
)alkoxy optionally substituted with one or more fluorine atoms, (C
1
-C
6
)alkoxy(C
1
-C
6
)alkyl, HO—(C═O)—, (C
1
-C
6
)alkyl-O—(C═O)—, HO—(C═O)—(C
1
-C
6
)alkyl, (C
1
-C
6
)alkyl-O—(C═O)—(C
1
-C
6
)alkyl, (C
1
-C
6
)alkyl-(C═O)—O—, (C
1
-C
6
)alkyl-(C═O)—O—(C
1
-C
6
)alkyl, H(O═C)—, H(O═C)—(C
1
-C
6
)alkyl, (C
1
-C
6
)alkyl(O═C)—, (C
1
-C
6
)alkyl(O═C)—(C
1
-C
6
)alkyl, NO
2
, amino, (C
1
-C
6
)alkylamino, [(C
1
-C
6
)alkyl]
2
amino, amino(C
1
-C
6
)alkyl, (C
1
-C
6
)alkylamino(C
1
-C
6
)alkyl, [(C
1
-C
6
)alkyl]
2
amino(C
1
-C
6
)alkyl, H
2
N—(C═O)—, (C
1
-C
6
)alkyl-NH—(C═O)—, [(C
1
-C
6
)alkyl]
2
N—(C═O)—, H
2
N(C═O)—(C
1
-C
6
)alkyl, (C
1
-C
6
)alkyl-HN(C═O)—(C
1
-C
6
)alkyl, [(C
1
-C
6
)alkyl]
2
N—(C═O)—(C
1
-C
6
)alkyl, H(O═C)—NH—, (C
1
-C
6
)alkyl(C═O)—NH, (C
1
-C
6
)alkyl(C

Affiliated with

Also associated with

Rating

Quinoxalinyl carboxylic acid derivatives does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Quinoxalinyl carboxylic acid derivatives, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Quinoxalinyl carboxylic acid derivatives will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-3332447